Drug Search Results
More Filters [+]

MK-0533

Alternative Names: mk-0533, mk0533, mk 0533
Latest Update: 2015-06-23
Latest Update Note: Clinical Trial Update

Product Description

MK-0533 is a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus. In comparison with PPAR_ full agonists, MK-0533 displayed diminished maximal activity (partial agonism) in cell-based transcription activation assays and attenuated gene signatures in adipose tissue.Ê (Sourced from: https://drugs.ncats.io/drug/J17152066B)

Mechanisms of Action: PPAR-g Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for MK-0533

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: General Diabetes|Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

12 week study of MK - 0533 in patients with T2DM

P2

Terminated

General Diabetes

2007-10-19

MK0533-005

P2

Terminated

Type 2 Diabetes

2007-08-01

Recent News Events

Date

Type

Title